This website contains information based on the Summary of Product Characteristics (SPC), as approved by the European Commission on Jivi (damoctog alfa pegol), Kovaltry (octocog alfa) and Kogenate FS (octocog alfa). It is intended to provide information to an international audience. In countries outside the EU, the local Product Information applies.
This unmodified, full length rFVIII features the same posttranslational modifications found in natural FVIII, and has a primary protein structure that has been in clinical use for over 25 years.1-3
A closer look at why post-translational modifications matter
Garger S, Severs J, Regan L, et al. BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics.Haemophilia. 2017;23(2):e67-e78.Return to content
Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92 (11):3983-3996Return to content
Kovaltry [Prescribing information]. Leverkusen, Germany: Bayer, 2017.Return to content
Leyte A, van Schijndel HB, Niehrs C, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol. Chem. 1991; 266 (2): 740-746.Return to content
Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJM, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005;3(6): 1257-1265.Return to content
Teare J M, et al. Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile of BAY 81-8973 compared with other full-length rFVIII products. Drug Des., Dev. Ther. 2019;13:941-8.Return to content